Sector News

Mallinckrodt buys respiratory drug maker to boost hospital presence

March 9, 2015
Life sciences
(Reuters) – Dublin-based drugmaker Mallinckrodt Plc strengthened its presence in U.S. hospitals as it agreed to buy privately held Ikaria Inc, a maker of a respiratory drug and its delivery system, for $2.3 billion.
 
Shares of Mallinckrodt, a seller of generics, specialty drugs and medical imaging agents, jumped as much as 6.7 percent to a record $123.95.
 
The deal gives Mallinckrodt access to INOmax, which Ikeria says is the only approved product to treat hypoxic respiratory failure in infants. The device that delivers nitric oxide has been available in the market for about a decade and a half.
 
Hypoxic respiratory failure affects about 25,000-30,000 babies born each year in the United States. INOmax currently caters to about half of that population, Mallinckrodt CEO Mark Trudeau said in a call on Thursday.
 
Ikaria, owned by a group of investors led by private equity firm Madison Dearborn Partners LLC, is testing INOmax for treating other breathing difficulties and a type of high blood pressure that affects arteries in the lungs and heart.
 
Madison Dearborn will get 2.8 times the $224 million it invested in Hampton, New Jersey-based Ikaria a little over a year ago, a person familiar with the matter said.
 
New Mountain Capital, which invested about $220 million in 2007, will receive as much as $880 million, other people familiar with the matter said.
 
Analysts from at least three brokerages — BMO Capital, Leerink Swann and Oppenheimer & Co — said the deal made sense for Mallinckrodt.
 
The deal comes a year after Mallinckrodt, spun off from Covidien Plc in 2013, bought Questcor Pharmaceuticals Inc for $5.2 billion.
 
Mallinckrodt, which claims to have its products in almost every U.S. hospital, diagnostic imaging center and pharmacy, said it expects Ikeria to add at least $150 million to its sales and 25 cents to earnings per share for the year ending September.
 
Mallinckrodt, which recorded sales of $866.3 million in its first quarter ended Dec. 26, plans to fund the deal with a combination of cash on hand and debt.
 
Goldman Sachs is Mallinckrodt’s financial adviser, and Wachtell Lipton Rosen & Katz and Arthur Cox in Ireland its legal advisers. Ikaria’s legal adviser is Kirkland & Ellis LLP.
 
Mallinckrodt shares were up 4.3 percent at $121.18 on the New York Stock Exchange in afternoon trading.
 
BY VIDYA L NATHAN AND GREG ROUMELIOTIS (Additional reporting by Rosmi Shaji in Bengaluru; Editing by Joyjeet Das)

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.